Patient Characteristics of CMV-Seropositive Patients Undergoing Autologous PBSC Transplantation
. | CD34-Selected . | Unselected . |
---|---|---|
No. of patients | 31 | 237 |
Median age (range) | 52 (5-62) | 48 (2-69) |
Gender (M/F) | 15/16 | 76/161 |
Diagnosis | ||
MM | 6 (19.4%) | 26 (11.0%) |
NHL | 10 (32.3%) | 38 (16.0%) |
HD | 1 (3.2%) | 12 (5.1%) |
ALL | 2 (6.5%) | — |
Breast cancer | 4 (12.9%) | 108 (45.6%) |
CLL | 4 (12.9%) | — |
Neuroblastoma | 1 (3.2%) | 11 (4.7%) |
Systemic sclerosis | 3 (9.7%) | — |
Ovarian cancer | — | 14 (5.9%) |
Germ cell | — | 2 (0.8%) |
AML | — | 9 (3.7%) |
CML | — | 5 (2.1%) |
Brain cancer | — | 1 (0.4%) |
Sarcoma | — | 7 (3.0%) |
Carcinoma | — | 4 (1.7%) |
Prior chemotherapy | ||
Median no. of regimens (range) | 2 (1-4) | 2 (1-6) |
Prior XRT | 6 (19.4%) | 68 (28.7%) |
High-dose regimen | ||
TBI-based | 14 (45.2%) | 34 (14.3%) |
Non–TBI-based | 17 (54.8%) | 203 (85.7%) |
No. of CD34 (×106 cells/kg) infused: | ||
Median (range) | 4.83 (2.34-14.64) | 6.97 (2.54-65.5) |
Posttransplant steroids | 11 (35.4%) | 74 (31.2%) |
. | CD34-Selected . | Unselected . |
---|---|---|
No. of patients | 31 | 237 |
Median age (range) | 52 (5-62) | 48 (2-69) |
Gender (M/F) | 15/16 | 76/161 |
Diagnosis | ||
MM | 6 (19.4%) | 26 (11.0%) |
NHL | 10 (32.3%) | 38 (16.0%) |
HD | 1 (3.2%) | 12 (5.1%) |
ALL | 2 (6.5%) | — |
Breast cancer | 4 (12.9%) | 108 (45.6%) |
CLL | 4 (12.9%) | — |
Neuroblastoma | 1 (3.2%) | 11 (4.7%) |
Systemic sclerosis | 3 (9.7%) | — |
Ovarian cancer | — | 14 (5.9%) |
Germ cell | — | 2 (0.8%) |
AML | — | 9 (3.7%) |
CML | — | 5 (2.1%) |
Brain cancer | — | 1 (0.4%) |
Sarcoma | — | 7 (3.0%) |
Carcinoma | — | 4 (1.7%) |
Prior chemotherapy | ||
Median no. of regimens (range) | 2 (1-4) | 2 (1-6) |
Prior XRT | 6 (19.4%) | 68 (28.7%) |
High-dose regimen | ||
TBI-based | 14 (45.2%) | 34 (14.3%) |
Non–TBI-based | 17 (54.8%) | 203 (85.7%) |
No. of CD34 (×106 cells/kg) infused: | ||
Median (range) | 4.83 (2.34-14.64) | 6.97 (2.54-65.5) |
Posttransplant steroids | 11 (35.4%) | 74 (31.2%) |